Advanced Solutions
for Advanced Pathology
CDX-2 (EPR2764Y
†
)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45278 IMPATH CDX-2 RTU R (EPR2764Y) 50 Tests
44256 CDX2 RTU R (EPR2764Y)
7 ml Ready To Use
44533 CDX2 0,1 R (EPR2764Y)
100 µl liquid Concentrated
44534 CDX2 1 R (EPR2764Y)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Colon
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CDX-2 is a caudal-related homeobox transcription factor whose expression in the adult is normally restricted to the intestinal epithelium. It is
implicated in the development and maintenance of the intestinal mucosa. This protein is expressed immunohistochemically in the nuclei of
normal intestinal epithelium. CDX-2 protein expression has been seen in gastrointestinal (GI) carcinomas, more so in lower GI than in upper GI.
Anti-CDX-2 has been useful to establish gastrointestinal origin of metastatic adenocarcinomas and carcinoids and is especially useful to
distinguish metastatic colorectal adenocarcinoma from lung adenocarcinoma. However, mucinous carcinomas of the ovary also stain positively
with this antibody, which limits the usefulness of this marker in the distinction of metastatic colorectal adenocarcinoma versus mucinous
carcinoma of the ovary.
Carcinomas
CDX-2
CK
Cocktail
CK 7
CK 20
pCEA CK 5
p63 β-Catenin TTF-1 Hep-Par1
Hepatocellular Carcinoma
-
-
-
-
+
-
-
-
+
(cytoplasmic)
+
Bladder Carcinoma
+
+
+
+
+
-
-
-
-
-
Salivary Gland Carcinoma
-
+
+
-
+
+
+
-
-
Lung Adenocarcinoma
-
+
+
-
+
-
-
-
+
-
Colorectal Adenocarcinoma
+
+
-
+
+
-
-
+
-
-
Cervical Carcinoma
-
+
+
-
+
-
-
-
-
-
Sweat Gland Carcinoma
-
+
+
-
+
+
+
-
-
Pancreatic Carcinoma
-
+
+
-
+
-
-
-
-
-
Gastric Carcinoma
+
+
+
-
+
-
-
-
-
-
Colon vs. Prostate Adenocarcinoma
CDX-2
CK 20
CEA
CA19-9
PSA
P504s
Colon Adenocarcinoma
+
+
+
+
-
+
Prostate Adenocarcinoma
-
-
-
-
+
+
Reference
1. Mazziotta RM, et al. Appl Immunohistochem Mol Morphol. 2005 Mar; 13(1):55-60.
85
